Volume 2 Issue 1
Jan.  2011
Turn off MathJax
Article Contents

doi: 10.3969/j.issn.1674-9081.2011.01.015
  • Received Date: 2010-09-30
  • Publish Date: 2011-01-30
  • loading
  • [1] Koeller JM.Clinical guidelines for the treatment of cancer related anemia[J].Pharmacotherapy, 1998, 18:156-169. doi:  10.1002/j.1875-9114.1998.tb03834.x/abstract
    [2] Crosby WH, Akeroyd JH.The limit of hemoglobin synthesis in hereditary hemolytic anemia; its relation to the excretion of bile pigment[J].Am J Med, 1952, 13:273-283. doi:  10.1016/0002-9343(52)90282-9
    [3] Hyman GA.Anemia in malignant neoplastic disease[J].J Chronic Dis, 1963, 16:645-666. doi:  10.1016/0021-9681(63)90003-1
    [4] Lawrence T.Anemia of chronic disease[J].N Engl J Med, 2005, 352:1011-1023. doi:  10.1056/NEJMra041809
    [5] Badzek S, Curic′Z, Krajina Z, et al.Treatment of Cancer-Related Anemia[J].Coll Antropol, 2008, 32:615-622. http://europepmc.org/abstract/MED/18756919
    [6] Nemeth E, Ganz T.The role of hepcidin in iron metabolism[J].Acta Haematol, 2009, 122:78-86. doi:  10.1159/000243791
    [7] Sasu BJ, Li H, Rose MJ, et al.Serumhepcidin but not prohepcidin may be an effective marker for anemia of inflammation (AI) [J].Blood Cells Mol Dis, 2010, 45:238-245. doi:  10.1016/j.bcmd.2010.07.013
    [8] Rivera S, Liu L, Nemeth E, et al.Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia[J].Blood, 2005, 105:1797-1802. doi:  10.1182/blood-2004-08-3375
    [9] Jong D, Eijkemans MJ, Lie Fong S, et al.Preoperative predictors for residual tumor after surgery in patients with ovarian carcinoma[J].Oncology, 2007, 72:293-301. doi:  10.1159/000113051
    [10] Adamson JW.The anemia of inflammation/malignancy:mechanisms and management[J].Hematol Am Soc Hematol Educ Program, 2008, 159-165. http://www.ncbi.nlm.nih.gov/pubmed/19074075
    [11] Ryan JL, Carroll JK, Ryan EP, et al.Mechanisms of Cancer-Related Fatigue[J].Oncologist, 2007, 12 (Suppl1) :22-34. http://www.ncbi.nlm.nih.gov/pubmed/17573453
    [12] Groopman JE, Itri LM.Chemotherapy-induced anemia in adults:incidence and treatment[J].J Natl Cancer Inst, 1999, 91:1616-1634. doi:  10.1093/jnci/91.19.1616
    [13] Kawada N, Moriyama T, Ichimaru N, et al.Negative effects of anemia on quality of life and its improvement by complete correction of anemia by administration of recombinant human erythropoietin in posttransplant patients[J].Clin Exp Nephrol, 2009, 13:355-360. doi:  10.1007/s10157-009-0170-x
    [14] Ludwig H, Van Belle S, Barrett-Lee P, et al.The European Cancer Anaemia Survey (ECAS) :a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anemia in cancer patients[J].Eur J Cancer, 2004, 40:2293-2306. doi:  10.1016/j.ejca.2004.06.019
    [15] Glaspy J, Meza L, Smith R, et al.Openlabel, phase Ⅰ/Ⅱ dose escalation study of ARANESP in patients with chronic anemia of cancer[J].Blood, 2000, 96:154b. http://www.researchgate.net/publication/298287575_Open-label_phase_iii_dose-escalation_study_of_aranesp_in_patients_with_chronic_anemia_of_cancer
    [16] Wenzel LB, Huang HQ, Armstrong DK, et al.Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer:a gynecologic oncology group study[J].J Clin Oncol, 2007, 25:437-443. doi:  10.1200/JCO.2006.07.3494
    [17] Cella D, Kallich J, McDermott A, et al.Relationship of hemoglobin, fatigue, and quality of life in anemic cancer patients[J].Ann Oncol, 2004, 15:979-986. doi:  10.1093/annonc/mdh235
    [18] Caro JJ, Salas M, Ward A, et al.Anemia as an independent prognostic factor for survival in patients with cancer:a systemic, quantitative review[J].Cancer, 2001, 91:2214-2221. doi:  10.1002/1097-0142(20010615)91:12<2214::AID-CNCR1251>3.0.CO;2-P
    [19] Dubsky P, Sevelda P, Jakesz R, et al.Anemia Is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy[J].Clin Cancer Res, 2008, 14:2082-2087. doi:  10.1158/1078-0432.CCR-07-2068
    [20] Lee SD, Park JW, Park KS, et al.Influence of anemia on tumor response to preoperative chemoradiotherapy for locally advanced rectal cancer[J].Int J Colorectal Dis, 2009, 24:1451-1458. doi:  10.1007/s00384-009-0762-7
    [21] Dubray B, Mosseri V, Brunin F, et al.Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer:a prospective study[J].Radiology, 1996, 201:553-558. doi:  10.1148/radiology.201.2.8888257
    [22] Rockwell S, Dobrucki IT, Kim EY, et al.Hypoxia and radiation therapy:Past history, ongoing research, and futurepromise[J].Curr Mol Med, 2009, 9:442-458. doi:  10.2174/156652409788167087
    [23] Vaupel P, Mayer A.Hypoxia in cancer:significance and impact on clinical outcome[J].Cancer Metastasis Rev, 2007, 26:225-239. doi:  10.1007/s10555-007-9055-1
    [24] Fyles AW, Milosevic M, Wong R, et al.Oxygenation predicts radiation response and survival in patients with cervix cancer[J].Radiother Oncol, 1998, 48:149-156. doi:  10.1016/S0167-8140(98)00044-9
    [25] Lin FK, Suggs S, Lin CH, et al.Cloning and expression of the human erythropoietin gene[J].Proc Natl Acad Sci USA, 1985, 82:7580-7584. doi:  10.1073/pnas.82.22.7580
    [26] Dagnelie PC, Pijls-Johannesma MC, Lambin P, et al.Impact of fatigue on overall quality of life in lung and breast cancer patients selected for high-dose radiotherapy[J].Ann Oncol.2007, 18:940-944. doi:  10.1093/annonc/mdm057
    [27] Bohlius J, Wilson J, Seidenfeld J, et al.Recombinant human erythropoietins and cancer patients:updated meta-analysis of 57 studies including 9353 patients[J].J Natl Cancer Inst, 2006, 17:708-714. http://www.tandfonline.com/servlet/linkout?suffix=CIT0010&dbid=8&doi=10.1185%2F03007995.2012.698602&key=16705125
    [28] Fandrey J.Erythropoietin receptors on tumor cells:what do they mean[J].Oncologist, 2008, 13 Suppl 3:16-20. http://www.ncbi.nlm.nih.gov/pubmed/18458120
    [29] Fu P, Jiang X, Arcasoy MO.Constitutively active erythropoietin receptor expression in breast cancer cells promotes cellular proliferation and migration through a MAP-kinase dependent pathway[J].Biochem Biophys Res Commun, 2009, 379:696-701. doi:  10.1016/j.bbrc.2008.12.146
    [30] Kumar SM, Acs G, Fang D, et al.Functional erythropoietin autocrine loop in melanoma[J].Am J Pathol, 2005, 166:823-830. doi:  10.1016/S0002-9440(10)62303-6
    [31] Brown WM, Maxwell P, Graham AN, et al.Erythropoietin receptor expression in non-small cell lung carcinoma:a question of antibody specificity[J].Stem Cells, 2007, 25:718-722. doi:  10.1634/stemcells.2006-0687
    [32] Lai SY, Childs EE, Xi S, et al.Erythropoietin-mediated activation of JAK-STATsignaling contributes to cellularinvasion in head and neck squamous cell carcinoma[J].Onco-gene, 2005, 24:4442-4449. doi:  10.1038/sj.onc.1208635
    [33] Pangalis GA, Siakantaris MP, Angelopoulou MK.Down-staging Rai stage IIIB chronic lymphocytic leukemia patients with the administration of recombinant human erythropoietin[J].Haematologica, 2002, 87:500-506. http://www.ncbi.nlm.nih.gov/pubmed/12010663
    [34] Jia HB, Jin Y, Ji Q, et al.Effects of recombinant human erythropoietin on neuropathic pain and cerebral expressions of cytokines and nuclear factor-kappa B[J].Can J Anaesth, 2009, 56:597-603. doi:  10.1007/s12630-009-9111-0
    [35] National Blood Data Resource Center.FAQs[DB/OL]. (2006-06-12) http://www.aabb.org/Documents/Programs-and-Services/NBDRC/faqs.htm.
    [36] Goodnough LT, Brecher ME, Kanter MH, et al.Transfusion medicine.First of two parts—blood transfusion[J].N Engl J Med, 1999, 340:438-447. doi:  10.1056/NEJM199902113400606
    [37] von Ahsen N, Muller C, Serke S, et al.Important role of nondiagnostic blood loss and blunted erythropoietic response in the anemia of medical intensive care patients[J].Crit Care Med, 1999, 27:2630-2639. doi:  10.1097/00003246-199912000-00005
    [38] Corwin HL, Gettinger A, Pearl RG, et al.The CRITStudy:Anemia and blood transfusion in the critically ill-current clinical practice in the United States[J].Crit Care Med, 2004, 32:39-52. doi:  10.1097/01.CCM.0000104112.34142.79
    [39] Bierbaum BE, Callaghan JJ, Galante JO, et al.An analysis of blood management in patients having a total hip or knee arthroplasty[J].J Bone Joint Surg Am, 1999, 81:2-10. doi:  10.2106/00004623-199901000-00002
    [40] Wu WC, Smith TS, Henderson WG, et al.Operative blood loss, blood transfusion, and 30-day mortality in older patients after major noncardiac surgery[J].Ann Surg, 2010, 252:11-17. doi:  10.1097/SLA.0b013e3181e3e43f
    [41] Shiba H, Ishida Y, Wakiyama S, et al.Negative impact of blood transfusion on recurrence and prognosis of hepatocellular carcinoma after hepatic resection[J].J Gastrointest Surg, 2009, 13:1636-1642. doi:  10.1007/s11605-009-0963-y
    [42] Benson D, Barnett CC Jr.Perioperative blood transfusions promote pancreas cancer progression[J/OL].J Surg Res (2010-06-17).http://www.journalofsurgicalresearch.com/search/quick.
    [43] Atzil S, Arad M, Glasner A, et al.Blood transfusion promotes cancer progression:a critical role for aged erythrocytes[J].Anesthesiology, 2008, 109:989-997. doi:  10.1097/ALN.0b013e31818ddb72
    [44] Ojima T, Iwahashi M, Nakamori M, et al.Association of allogeneic blood transfusions and long-term survival of patients with gastric cancer after curative gastrectomy[J].J Gastrointest Surg, 2009, 13:1821-1830. doi:  10.1007/s11605-009-0973-9
    [45] National Comprehensive Cancer Network.Comments in response to the proposed decision memo (CAG00383N) for erythropoiesis stimulating agents (ESAs) for non-renal disease indications[DB/OL]. (2007-06-12).http://www.nccn.org/professionals/physician-gls/PDF/mds.pdf.
    [46] Kaye P, Abdulla K, Wood J, et al.Iron-induced mucosal pathology of the upper gastrointestinal tract:a common finding in patients on oral iron therapy[J].Histopathology, 2008, 53:311-317. doi:  10.1111/j.1365-2559.2008.03081.x
    [47] Rozen-Zvi B, Gafter-Gvili A, Paul M, et al.Intravenous Versus oral iron supplementation for the treatment of anemia in CKD:systematic review and meta-analysis[J].Am J Kidney Dis, 2008, 52:897-906. doi:  10.1053/j.ajkd.2008.05.033
    [48] Auerbach M, Ballard H, Glaspy J.Clinical update:intravenous iron foranaemia[J].Lancet, 2007, 369:1502-1504. doi:  10.1016/S0140-6736(07)60689-8
    [49] Chao-Hung Ho, Yuan-Bin Yu, Ping-Hao.The prevalence of iron deficiency anemia and its clinical implications in patients with colorectal carcinoma[J].J Chin Med Assoc, 2008, 71:119-122. doi:  10.1016/S1726-4901(08)70002-9
    [50] Sworczak K, Siekierska HM, Drobinska A, et al.Iron deficiency anemia as the sole symptomof small intestine carcinoma[J].Med Sci Monit, 2001, 7:457-460. http://europepmc.org/abstract/MED/11386025
    [51] Carter D, Maor Y, Bar-Meir S, et al.Prevalence and predictive signs for gastrointestinal lesions in premenopausal women with iron deficiency anemia[J].Dig Dis Sci, 2008, 53:3138-3144. doi:  10.1007/s10620-008-0298-7
  • 加载中


    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (131) PDF downloads(9) Cited by()
    Proportional views


    DownLoad:  Full-Size Img  PowerPoint